MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2022.02.009

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2022

Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.

Halahleh Khalid, Al Sawajneh Suhaib, Saleh Yacob, Shahin Omar, Abufara Alaa, Ma'koseh Mohamad, Abdel-Razeq Rashid, Barakat Fareed, Abdelkhaleq Hadeel, Al-Hassan Nadira, Atiyyat Reem, Al-Faker Noor, Omari Zaid, Ghatasheh Hamza, Jaradat Imad, Muradi Isa, Iyad Sultan, Bazarbachi Ali

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Checkpoint inhibitors demonstrated significant efficacy in relapsed/refractory Hodgkin's Lymphoma (R/R cHL) resulting in high responses and prolonged progression free survival in patients, who relapse after or are ineligible for autologous stem cell transplantation (auto-SCT). We aimed to assess the efficacy and toxicity of Pembrolizumab before auto-SCT and in transplant naïve patients and calculate survival outcomes.

PATIENTS AND

METHODS

Fifty-five patients with R/R cHL were included. Patients demographics, including age, sex, risk stratification, therapy received and details pertaining transplantation, were collected.

RESULTS

Median age was 28 years (range, 16-62 years). The median follow-up was 15.3 months and the median number of previous treatments was 3 (1-10). The best objective response was 74.5% (CR 32.7%, SD 5.5%) with reasonable safety profile. Twenty-nine of the responding patients received subsequent auto-SCT and 9 allogeneic stem cell transplantation (allo-SCT), 6 are currently alive with ongoing response. At the time of analysis, 6 patients remained on Pembrolizumab and the rest discontinued. The main reason for discontinuation was disease progression (n-49). Twelve-months overall survival and progression free survival (PFS) was 92% (95% CI: 76%-95%) and 51% (95% CI, 39%-67%) respectively. Twelve-month PFS for patients, who achieved CR or PR or PD was 88% (95% CI: 07%-75%); PR 60% (95% CI: 21%-29%) and 5% (95% CI: 5%-0%). Though the number of patients who received auto-SCT after Pembrolizumab was small (n-15), 12 months overall survival and PFS 100% and PFS 92%. 11 patients (20%) deceased during the follow-up and none was regarded to be treatment-related.

CONCLUSION

Checkpoint inhibitors are effective in heavily pretreated cHL patients with reasonable survival outcomes. The results supporting the concept of auto and/or allo-SCT after checkpoint inhibitors use.

Для цитирования: Halahleh Khalid, Al Sawajneh Suhaib, Saleh Yacob, Shahin Omar, Abufara Alaa, Ma'koseh Mohamad, Abdel-Razeq Rashid, Barakat Fareed, Abdelkhaleq Hadeel, Al-Hassan Nadira, Atiyyat Reem, Al-Faker Noor, Omari Zaid, Ghatasheh Hamza, Jaradat Imad, Muradi Isa, Iyad Sultan, Bazarbachi Ali. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.. Clinical lymphoma, myeloma & leukemia. 2022. DOI: 10.1016/j.clml.2022.02.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.